Following the announcement on 15th December 2016, regarding the contemplated acquisition of Capsugel, Lonza has successfully placed 5 million new shares, raising CHF 865m
The new shares were offered to a combination of private placement investors and buyers outside of Switzerland to institutional investors and qualified institutional buyers.
Lonza, a custom manufacturer of active pharmaceutical ingredients and nutraceuticals, has stated that the funds will be used to partially fund the contemplated take-over of Capsugel.
This acquisition is expected to be complete by the end of the 2nd-quarter of 2017.
Lonza, which is currently based in Switzerland, the new shares are expected to be listed on the SIX Swiss Exchange on 3 February 2017. Payment and settlement of this transaction is expected take place on the same date.